Caris Life Sciences
202 hedge funds and large institutions have $2.8B invested in Caris Life Sciences in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 88 increasing their positions, 38 reducing their positions, and 35 closing their positions.
132% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 38
63% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 35
9% more funds holding
Funds holding: 186 → 202 (+16)
4.01% more ownership
Funds ownership: 51.5% → 55.51% (+4%)
20% less call options, than puts
Call options by funds: $4.57M | Put options by funds: $5.71M
29% less capital invested
Capital invested by funds: $3.92B → $2.8B (-$1.12B)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$362M |
| 2 |
BlackRock
New York
|
+$54.3M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$50M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$41.4M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$25.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSP
Sixth Street Partners
Dallas,
Texas
|
-$109M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$79.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$66.4M |
| 4 |
Millennium Management
New York
|
-$46.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$44.8M |
CAI Hedge Fund Activity: Q1 2026 in Review
202 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q1 2026, worth a combined $2.8B — down 29% from $3.92B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new CAI positions and 35 closed out — a net gain of 22 holders — while 88 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $362M. The largest seller was Sixth Street Partners, cutting an estimated $109M.
- 202 institutional investors held Caris Life Sciences (CAI) as of Q1 2026, up from 186 in Q4 2025.
- Funds reported $2.8B of Caris Life Sciences stock for Q1 2026, down 29% quarter-over-quarter.
- 57 funds opened new Caris Life Sciences positions in Q1 2026 and 35 closed out, a net change of +22 holders.
- The largest Caris Life Sciences buyer in Q1 2026 was Fidelity Investments, an estimated $362M added.
- The largest Caris Life Sciences seller in Q1 2026 was Sixth Street Partners, an estimated $109M sold.
Based on aggregated 13F filings for Q1 2026.